ABUS Arbutus Biopharma Corporation - Common Stock
$5,01
Harga · Agu 19, 2026
Fundamental per Agu 12, 2026
Rentang 52M
$3–$5
82% of range
Peringkat Analis
BUY
8 analysts
Target Harga
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
Margin Laba Bersih
-237.9%
Tentang Arbutus Biopharma Corporation - Common Stock Tinjauan perusahaan dari Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Baca selengkapnya
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
ABUS Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$5.01
Kapitalisasi Pasar
$987M
P/E (TTM)
-30.1
EPS (TTM)
$-0.17
Pendapatan (TTM)
$14M
Imbal Hasil Dividen
—
ROE
-42.0%
D/E Utang/Ekuitas
—
Rentang 52M
$3 – $5
ABUS Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Configure
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan & Laba Bersih
$14M
2016-12-31
→
2025-12-31
EPS
$-0.17
2016-12-31
→
2025-12-31
Arus Kas Bebas
$-40M
2016-12-31
→
2025-12-31
Margin
-237.9%
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
Metrik
Tren 5 Tahun
ABUS
Median Rekan
P/E (TTM)
-30.1
6.7
P/S (TTM)
70.1
39.8
P/B
12.9
4.8
Price / FCF (Harga / FCF)
-24.9
—
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Metrik
Tren 5 Tahun
ABUS
Median Rekan
Operating Margin (Margin Operasi)
-271.0%
—
Net Profit Margin (Margin Laba Bersih)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
Metrik
Tren 5 Tahun
ABUS
Median Rekan
Current Ratio (Rasio Lancar)
15.7
9.7
Quick Ratio (Rasio Cepat)
15.5
—
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Metrik
Tren 5 Tahun
ABUS
Median Rekan
Revenue YoY (Pendapatan YoY)
128.2%
—
Revenue CAGR 3Y (CAGR Pendapatan 3T)
-28.8%
—
Revenue CAGR 5Y (CAGR Pendapatan 5T)
15.3%
—
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Metrik
Tren 5 Tahun
ABUS
Median Rekan
ABUS Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
BELI
8 analis
- Beli Kuat 3 37,5%
- Beli 4 50,0%
- Tahan 1 12,5%
- Jual 0 0,0%
- Jual Kuat 0 0,0%
Target Harga 12 Bulan
1 analis · 2026-08-17
Rendah
$5.53
Tinggi
$5.53
Target median
$5.53
+10,3%
Target rata-rata
$5.53
+10,3%
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
0.01%
| Periode | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|
| 31 Maret 2026 | $-0.05 | $-0.03 | -0.02% |
| 31 Des. 2025 | $-0.02 | $-0.04 | 0.02% |
| 30 Sep. 2025 | $-0.04 | $-0.03 | -0.01% |
| 30 Juni 2025 | $0.01 | $-0.05 | 0.06% |
| 31 Maret 2025 | $-0.13 | $-0.11 | -0.02% |
| 31 Des. 2024 | $-0.07 | $-0.08 | 0.01% |
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi 16
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Neraca 25
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Arus Kas 14
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Profitabilitas 7
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Likuiditas & Solvabilitas 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Efisiensi 2
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Tingkat Pertumbuhan 3
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM) 10
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Laporan Laba Rugi 16
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Neraca 22
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Arus Kas 11
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Profitabilitas 7
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Likuiditas & Solvabilitas 3
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Efisiensi 2
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Valuasi (TTM) 10
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Pendapatan | $14M | $6M | $18M | $39M | $11M |
| Margin Operasi % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Laba Bersih | $-34M | $-70M | $-73M | $-69M | $-76M |
| EPS Dilusian | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Neraca
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rasio Lancar | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Rasio Cepat | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
Arus Kas
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-40M | $-65M | $-87M | $-36M | $-68M |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F) 191 pengaju · $496.0M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 41 (+15 vs Kuartal sebelumnya) | 22 (-8 vs Kuartal sebelumnya) | 55 (+10 vs Kuartal sebelumnya) | 44 (-8 vs Kuartal sebelumnya) | +14.8M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| Two Seas Capital LP | $91.658.798 | 19.095.583 | 18,48% | Saham |
| Whitefort Capital Management, LP | $75.812.453 | 15.794.261 | 15,28% | Saham |
| VANGUARD GROUP INC | $38.412.670 | 7.986.002 | 7,74% | Saham |
| STATE STREET CORP | $37.772.059 | 7.869.179 | 7,62% | Saham |
| Rubric Capital Management LP | $36.158.098 | 7.532.937 | 7,29% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.651.259 | 7.010.679 | 6,78% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $16.983.987 | 3.537.471 | 3,42% | Saham |
| BlackBarn Capital Partners LP | $12.000.000 | 2.500.000 | 2,42% | Saham |
| Woodline Partners LP | $10.952.909 | 2.281.856 | 2,21% | Saham |
| GOLDMAN SACHS GROUP INC | $8.545.829 | 1.780.381 | 1,72% | Saham |
| Jefferies Financial Group Inc. | $8.216.026 | 1.711.672 | 1,66% | Saham |
| NOMURA HOLDINGS INC | $7.857.989 | 1.637.081 | 1,58% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.398.998 | 1.541.458 | 1,49% | Saham |
| BANK OF AMERICA CORP /DE/ | $7.169.851 | 1.493.719 | 1,45% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6.869.846 | 1.431.218 | 1,38% | Saham |
| OSAIC HOLDINGS, INC. | $6.469.756 | 1.347.866 | 1,30% | Saham |
| ADAR1 Capital Management, LLC | $6.087.106 | 1.268.147 | 1,23% | Saham |
| Deltroit Asset Management (UK) LLP | $5.760.000 | 1.200.000 | 1,16% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $5.449.738 | 1.135.362 | 1,10% | Saham |
| CITIGROUP INC | $4.175.784 | 869.955 | 0,84% | Saham |
| BANK OF MONTREAL /CAN/ | $3.734.102 | 777.938 | 0,75% | Saham |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3.123.360 | 650.700 | 0,63% | Saham |
| MACKENZIE FINANCIAL CORP | $2.946.269 | 613.806 | 0,59% | Saham |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2.889.638 | 602.008 | 0,58% | Saham |
| Western Standard LLC | $2.605.378 | 542.787 | 0,53% | Saham |
| Rangeley Capital, LLC | $2.400.000 | 500.000 | 0,48% | Saham |
| Man Group plc | $2.272.642 | 473.467 | 0,46% | Saham |
| Corbin Capital Partners, L.P. | $2.231.732 | 682.487 | 0,45% | Saham |
| CenterBook Partners LP | $2.136.725 | 445.151 | 0,43% | Saham |
| Freestone Capital Holdings, LLC | $2.124.000 | 442.500 | 0,43% | Saham |
| CITADEL ADVISORS LLC | $1.942.541 | 404.696 | 0,39% | Saham |
| KENNEDY CAPITAL MANAGEMENT LLC | $1.849.430 | 385.298 | 0,37% | Saham |
| Swiss National Bank | $1.375.200 | 286.500 | 0,28% | Saham |
| Ledgewood Wealth Advisors, LLC | $1.336.493 | 278.436 | 0,27% | Saham |
| FMR LLC | $1.277.232 | 266.090 | 0,26% | Saham |
| Susquehanna Portfolio Strategies, LLC | $1.265.688 | 263.685 | 0,26% | Saham |
| Carrera Capital Advisors | $1.234.402 | 257.167 | 0,25% | Saham |
| Quinn Opportunity Partners LLC | $1.225.027 | 255.214 | 0,25% | Saham |
| D. E. Shaw & Co., Inc. | $1.209.614 | 252.003 | 0,24% | Saham |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.161.682 | 242.017 | 0,23% | Saham |
| Campbell & CO Investment Adviser LLC | $1.106.563 | 230.534 | 0,22% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.080.475 | 225.099 | 0,22% | Saham |
| Squarepoint Ops LLC | $999.096 | 208.145 | 0,20% | Saham |
| MARTINGALE ASSET MANAGEMENT L P | $926.880 | 193.100 | 0,19% | Saham |
| RHUMBLINE ADVISERS | $909.224 | 189.423 | 0,18% | Saham |
| STRS OHIO | $810.720 | 168.900 | 0,16% | Saham |
| Bank of New York Mellon Corp | $801.067 | 166.889 | 0,16% | Saham |
| Caption Management, LLC | $720.000 | 150.000 | 0,15% | Opsi beli |
| Caption Management, LLC | $720.000 | 150.000 | 0,15% | Opsi jual |
| Hudson Bay Capital Management LP | $720.000 | 150.000 | 0,15% | Saham |
| Wealth Management Associates, Inc. | $710.376 | 147.995 | 0,14% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $701.467 | 146.139 | 0,14% | Saham |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643.433 | 142.985 | 0,13% | Saham |
| ALLIANCEBERNSTEIN L.P. | $631.080 | 140.240 | 0,13% | Saham |
| Connor, Clark & Lunn Investment Management Ltd. | $619.685 | 129.101 | 0,12% | Saham |
| BlackRock, Inc. | $567.398 | 118.208 | 0,11% | Saham |
| Front Row Advisors LLC | $516.035 | 110.500 | 0,10% | Saham |
| BARCLAYS PLC | $499.320 | 104.025 | 0,10% | Saham |
| Rafferty Asset Management, LLC | $490.416 | 102.170 | 0,10% | Saham |
| MetLife Investment Management, LLC | $452.885 | 94.351 | 0,09% | Saham |
| VANGUARD ASSET MANAGEMENT, Ltd | $429.994 | 89.582 | 0,09% | Saham |
| TWO SIGMA INVESTMENTS, LP | $407.933 | 84.986 | 0,08% | Saham |
| JBF Capital, Inc. | $385.349 | 80.281 | 0,08% | Saham |
| Integrated Quantitative Investments LLC | $383.698 | 79.937 | 0,08% | Saham |
| Virtus Investment Advisers, LLC | $368.674 | 76.807 | 0,07% | Saham |
| XTX Topco Ltd | $365.808 | 76.210 | 0,07% | Saham |
| AMERICAN CENTURY COMPANIES INC | $317.832 | 66.215 | 0,06% | Saham |
| Invesco Ltd. | $305.616 | 63.670 | 0,06% | Saham |
| Rockefeller Capital Management L.P. | $302.400 | 63.000 | 0,06% | Saham |
| Creative Planning | $298.133 | 62.111 | 0,06% | Saham |
| JANUS HENDERSON GROUP PLC | $273.746 | 60.900 | 0,06% | Saham |
| Quantinno Capital Management LP | $273.413 | 56.961 | 0,06% | Saham |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265.118 | 55.233 | 0,05% | Saham |
| Vanguard Global Advisers, LLC | $264.730 | 55.152 | 0,05% | Saham |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255.936 | 53.320 | 0,05% | Saham |
| Jump Financial, LLC | $255.178 | 53.162 | 0,05% | Saham |
| PROFUND ADVISORS LLC | $254.482 | 53.017 | 0,05% | Saham |
| WOLVERINE TRADING, LLC | $248.868 | 55.800 | 0,05% | Opsi beli |
| Police & Firemen's Retirement System of New Jersey | $248.203 | 51.709 | 0,05% | Saham |
| Exome Asset Management LLC | $240.797 | 50.166 | 0,05% | Saham |
| Magnetar Financial LLC | $225.922 | 47.067 | 0,05% | Saham |
| State of New Jersey Common Pension Fund D | $221.602 | 46.167 | 0,04% | Saham |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212.664 | 44.305 | 0,04% | Saham |
| ALLSTATE CORP | $212.285 | 44.226 | 0,04% | Saham |
| Quadrature Capital Ltd | $201.619 | 42.004 | 0,04% | Saham |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189.475 | 39.474 | 0,04% | Saham |
| ARIZONA STATE RETIREMENT SYSTEM | $189.110 | 39.398 | 0,04% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175.680 | 36.600 | 0,04% | Opsi beli |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171.936 | 35.820 | 0,03% | Saham |
| NEW YORK STATE COMMON RETIREMENT FUND | $169.286 | 35.268 | 0,03% | Saham |
| INTECH INVESTMENT MANAGEMENT LLC | $167.208 | 34.835 | 0,03% | Saham |
| Mitsubishi UFJ Trust & Banking Corp | $152.102 | 31.688 | 0,03% | Saham |
| VOYA INVESTMENT MANAGEMENT LLC | $151.070 | 31.473 | 0,03% | Saham |
| China Universal Asset Management Co., Ltd. | $150.902 | 31.438 | 0,03% | Saham |
| Vanguard Investments Australia, Ltd. | $150.182 | 31.288 | 0,03% | Saham |
| KLP KAPITALFORVALTNING AS | $148.320 | 30.900 | 0,03% | Saham |
| Premier Path Wealth Partners, LLC | $144.000 | 30.000 | 0,03% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $139.675 | 29.099 | 0,03% | Saham |
| SHERBROOKE PARK ADVISERS LLC | $134.627 | 27.989 | 0,03% | Saham |
| EntryPoint Capital, LLC | $134.112 | 27.940 | 0,03% | Saham |
Orang dalam perusahaan 25 orang dalam · 13 pejabat · 11 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 24 Juni 2019 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 1 Maret 2019 A | 341.396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 1 Maret 2019 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 Maret 2017 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 1 Maret 2019 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 1 Maret 2019 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 1 Maret 2019 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 1 Maret 2019 A | 1.503.403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 Des. 2018 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 April 2018 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 Maret 2017 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 Agu 2016 M | 42.097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 Maret 2016 A | — | 0 | 0 | $0 |
| Roger Sawhney | Direktur | 8 Juni 2026 A | — | 0 | 0 | $0 |
| Robert A Beardsley | Direktur | 8 Juni 2026 A | — | 0 | 0 | $0 |
| Frank Torti | Direktur | 26 Nov. 2018 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | Direktur | 19 Juni 2018 A | — | 0 | 0 | $0 |
| Keith S Manchester | Direktur | 19 Juni 2018 A | — | 0 | 0 | $0 |
| Daniel D Burgess | Direktur | 19 Juni 2018 A | — | 0 | 0 | $0 |
| Herbert J Conrad | Direktur | 19 Juni 2018 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | Direktur | 19 Juni 2018 A | 1.000 | 0 | 0 | $0 |
| Frank Karbe | Direktur | 21 Juni 2017 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | Pemilik 10% | 18 Okt. 2021 C | 38.847.462 | 0 | 0 | $0 |
| Andrew Lo | Pemilik 10% | 12 Jan. 2018 P | — | 0 | 0 | $0 |
| Patrick Machado | Pemilik 10% | 12 Jan. 2018 P | — | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+ 8 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 pengajuan | 28 April 2026 | 8,00% | Amandemen | — | SEC |
| Roivant Sciences Ltd. ×14 pengajuan | 25 Feb. 2025 | 20,50% | Amandemen | — | SEC |
| Patrick Machado ×4 pengajuan | 17 Juli 2019 | — | Pengajuan awal | — | SEC |
| Dr. Andrew Lo ×5 pengajuan | 17 Juli 2019 | — | Pengajuan awal | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 pengajuan | 12 Juli 2019 | — | Pengajuan awal | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 pengajuan | 12 Juli 2019 | — | Pengajuan awal | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 pengajuan | 12 Juli 2019 | — | Pengajuan awal | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 pengajuan | 12 Juli 2019 | — | Pengajuan awal | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF Dimiliki oleh 34 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,66% | 58.600 NS | 30 April 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 24.523 SH | 8 Agu 2026 | Harian |
| IWC · iShares Trust | 0,17% | 546.359 SH | 8 Agu 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,11% | 132.235 NS | 30 April 2026 | N-PORT |
| SMMV · iShares Trust | 0,10% | 62.236 SH | 8 Agu 2026 | Harian |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,06% | 10.748 SH | 8 Agu 2026 | Harian |
| IBB · iShares Trust | 0,06% | 1.164.301 SH | 8 Agu 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,05% | 172.487 SH | 8 Agu 2026 | Harian |
| IWO · iShares Trust | 0,04% | 1.441.824 SH | 8 Agu 2026 | Harian |
| BIB · ProShares Trust | 0,04% | 7.110 NS | 31 Mei 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,03% | 64.366 NS | 31 Mei 2026 | N-PORT |
| IWM · iShares Trust | 0,02% | 4.026.921 SH | 8 Agu 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 925.044 SH | 8 Agu 2026 | Harian |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 122.366 SH | 8 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,02% | 65.520 NS | 30 April 2026 | N-PORT |
| ITWO · ProShares Trust | 0,02% | 7.126 NS | 31 Mei 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 734.401 NS | 31 Mei 2026 | N-PORT |
| ISCG · iShares Trust | 0,01% | 24.628 SH | 8 Agu 2026 | Harian |
| ISCB · iShares Trust | 0,01% | 6.673 SH | 8 Agu 2026 | Harian |
| UWM · ProShares Trust | 0,01% | 5.554 NS | 31 Mei 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 1.810.587 SH | 8 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 430.244 SH | 8 Agu 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 64.437 NS | 30 April 2026 | N-PORT |
| ISCV · iShares Trust | 0,01% | 13.314 SH | 8 Agu 2026 | Harian |
| WSML · iShares Trust | 0,01% | 11.503 SH | 8 Agu 2026 | Harian |
| URTY · ProShares Trust | 0,01% | 5.639 NS | 31 Mei 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 5.309 NS | 31 Mei 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 141 NS | 31 Mei 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 266.009 SH | 8 Agu 2026 | Harian |
| IWV · iShares Trust | 0,00% | 49.253 SH | 8 Agu 2026 | Harian |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 86.163 NS | 31 Mei 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 4.760 NS | 31 Mei 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.034.547 SH | 8 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.683 SH | 8 Agu 2026 | Harian |